Nature's Sunshine Products Inc (NATR): Shareholders' Equity
$161.55M
As of 2025-12-31
$169.32M
As of 2026-06-30
+3.2%
3-year compound annual growth
+0.5%
5-year compound annual growth
+1.7%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $161.55M | +0.3% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $160.99M | +0.9% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $159.54M | +8.5% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $147.05M | -8.9% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $161.40M | +2.7% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $157.23M | +21.5% | 2023-03-16, Balance as of period end |
| 2019-12-31 | $129.44M | +7.4% | 2021-03-10, Balance as of period end |
| 2018-12-31 | $120.57M | +0.7% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $119.73M | -9.6% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $132.40M | -2.8% | 2019-03-08, Balance as of period end |
| 2015-12-31 | $136.26M | +5.7% | 2018-03-16, Balance as of period end |
| 2014-12-31 | $128.96M | +22.5% | 2017-03-14, Balance as of period end |
| 2013-12-31 | $105.26M | -9.0% | 2016-03-14, Balance as of period end |
| 2012-12-31 | $115.64M | +32.2% | 2015-03-13, Balance as of period end |
| 2011-12-31 | $87.44M | +27.9% | 2014-03-17, Balance as of period end |
| 2010-12-31 | $68.38M | +19.8% | 2013-03-07, Balance as of period end |
| 2009-12-31 | $57.09M | n/a | 2012-03-05, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $114.83M | +94.4% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$2.09B | n/m |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $715.50M | -14.9% |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | $314.69M | +39.5% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $1.25B | +62.1% |
| Innoviva, Inc. (INVA) | 2025-12-31 | $1.17B | +69.7% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $300.13M | +14.2% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $166.95M | -3.7% |
Compare NATR, TVTX, BBIO, ZLAB side by side · Screen every company in Pharmaceutical Preparations ↗